HomeDiscoveryMeetings and congressesMeetings and congresses 2016

Meetings and congresses 2016


Novembre 29 - Dicembre 2
28th EORTC-NCI-AACR Symposium "Molecular targets and cancer therapeutics
Monaco, Germany
Web link
Abstract 388
NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapies

Ottobre 13-15
Cancer bio-immunotherapy - XIV NIBIT Meeting
Siena, Italy
Web link

Ottobre 10-13
7th Annual ADC Summit meeting
San Diego, CA
Web link
Abstract 24
NMS-P945: a novel highly active thienoindole payload for antibody drug conjugation generation

Settembre 11
XXIV National Meeting on Medicinal Chemistry
Perugia, Italy
Web link

Agosto 28 - Settembre 1
XXIV EFMC International Symposium on Medicinal Chemistry
Berlin, Germany
Web link

Luglio 15-16
Fifth International Chordoma Research Workshop
Boston, USA
Web link

Giugno 15-17
13th Annual Meeting of the Bioinformatics Italian Society
Fischiano, Italy
Web link

Giugno 13-14
17th Annual Drug Discovery Summit 2016
Berlin, Germany
Web link

Maggio 25
S. Palomba, Italy
Web link
Oral presentation
Liquid Chromatography - Mass Spectrometry: Where we are now and where we are going (A perfect troubled marriage II)

Maggio 12
Medicina di precisione e target in oncologia
Milan, Italy
Web link

Aprile 16-20
AACR Annual Meeting
Ernest N. Morial Convention Center
New Orleans, Louisiana, USA.
Web link
Abstract 1223
NMS-P293, a novel potent and selective PARP-1 inhibitor with high anti-tumor efficacy and tolerability
Abstract 3795
Novel and selective MELK kinase inhibitors active in breast cancer cell lines
Abstract 2136
Entrectinib is effective against the gatekeeper and other emerging resistance mutations in NTRK-, ROS1- and ALK- rearranged cancers
Abstract 2690
A Novel Antibody-Drug Conjugate Directed to the ALK Receptor Tyrosine Kinase Demonstrates Efficacy in Models of Neuroblastoma

Marzo 9-12
Hematological malignancies from mechanism to therapy symposium
Web link
Abstract B4
NMS-P088, a novel dual FLT3-KIT inhibitor with an excellent preclinical therapeutic window suitable for therapy of AML, including cases harboring gatekeeper mutations variants

Gennaio 22
Innovative therapy, monoclonal antibodies and beyond, 6th edition
Milan, Italy
Web link